Whilst acute or chronic elevation of peripheral endocannabinoid levels is accompanied by, and may contribute to, metabolic disorders in obese animals and human subjects, counteraction of CB1 activity with selective inverse agonists or antagonists reduces obesity and several ensuing metabolic disorders and counteracts the dysmetabolic effects of a HFD in rodents [11]. This evidence concerns the gene CNR1 and metabolic disease.